[6-MWD = (74.31 X physical activity level) + (33.88 X gender) À (4.25 X age) + 342.650]. This equation explained 67.8% of the distance variance.
Aim: The aim of this work was to determine the prevalence of tricuspid valve disease among rheumatic heart disease patient in the cardiac center in TMGH outpatient. STUDY DESIGN: descriptive prospective study Methods: we enrolled all adult patients who had been referred to an echocardiography outpatient Echo Lab. Over 3 months time from 1/5/2009 to 1/8/2009 Setting: cardiac center,Al-Thawra General Hospital, Sana'a city,Yemen.
Results: 172 cases (34.4%) were having Rheumatic heart disease out of 500 cases referred to the Echo lab. Organic tricuspid valve disease was found in 33 patients (19.2%). 88 cases (51.1%) were having functional (secondary) tricuspid valve disease. while normal tricuspid valves were found in 51 cases (29.7%). Pulmonary Hypertension was found in 115 cases (66.8%); 27 cases had sever PH (15.7%),25 cases had moderate PH(14.5%),63 cases had mild PH(36.6%) and 57 cases had normal pulmonary tension.
Right atrial enlargement was found in 24 cases (14%).while no comment on atrial size in 29 cases (16.9%),119 cases were having normal RA size. 20 patients (11.6%) were having right ventricular enlargement, no comment on 31 cases (18%) while 121 cases had normal RV size.
Conclusion: High prevalence of tricuspid valve disease among the rheumatic heart disease either organic affection or functional (secondary).Tricuspid Valve Diseases need special care before surgery as both organic and functional tricuspid diseases need to be managed surgically in most cases. Functional tricuspid regurge (FTR) is an important dilemma in cardiac surgery, and tricuspid annular dilation is a reliable indicator of the degree of FTR. Many methods are available for repair: Ring repair is believed to be more durable than suture annuloplasty, however the suture repair still holds a place. This work was conducted over 60 patients with history of rheumatic heart disease with predominance mitral valve diseases, pulmonary hypertension (PH) and FTR.Group I : 30 patients had ADVTA using intraoperative TEE. Group II: 30 patients had conventional De Vega tricuspid annuloplasty(CDVTA). The two groups were assessed immediately and six months later by TTE. There was a significant relation between PH and tricuspid valve annulus diameter (TVAD) in Group I (mean TVAD in PH grade 2 is 38.0+6.5 mm, while in PH grade 3 mean TVAD is 41.1+4.6). Also PH correlates significantly with TVAD in Group II. Results showed advantage of ADVTA in avoiding postoperative residual TR due to accurate application of tension(Preoperative FTR grade 2 in 12 patients and FTR grade 3 in 18 patients, immediate postoperative TR grade 2 in 4 patients and no patient in TRgrade 3,late postoperative TR grade 2 in 6 patients and TR grade 3 in one patient). Results demonstrated superiority of ADVTA in decreasing postoperative diastolic gradient(PODG) on tricuspid valve and in avoiding tricuspid stenosis (immediate PODG in Group I is 5.4+3.2 mmHg and 9.1+3.3mmHg in Group II, late PODG in Group I is 5.9+3.3 mmHg and 9.9+3.5 mmHg in Group II). ADVTA guided by TEE still holds a place as it is quick, inexpensive, devoid of use of foreign body especially in the presence of infection, and showed durability.
http://dx.doi:10.1016/j.jsha.2013.03.160 pts (70.6%, however all of them underwent intracardiac echo guided imaging during the ablation procedure. 40 pts underwent manual RF ablation using CARTO, 40 pts underwent ablation using NavX system, 70 pts underwent robotic ablation using Sensui system. Pulmonary vein isolation was done to all pts using either pulmonary vein (PV) antral isolation in 116 (77.3%) or circumferential pulmonary vein ablation in 34 pts (22.7%). Circumferential PV ablation was usually associated with posterior wall ablation. All pts were followed at 3, 6, 9, and 12 months.
Results: 34 Patients (22.6%) developed early recurrence of AF after an initial blanking period of 3 months. We had 16 patients(10.6%) with treatment failure at short term follow up, this number increased to 18 patients (12%) at midterm follow up and further small increase to 20 patients (13.3%) at long term follow up, recurrences were any episode of AF and/or AFL/AT > 30 s after the blanking period. The incidence of recurrence of AF in males was 13% (11/86), 14% in females (9/64), P NS.Comparison between manual and robotic groups as regards ablation points. Comparison of effect of rate control versus rhythm control on LV function in patients with AF and ischemic heart failure Samir Rafla, Kamal Mahmoud, Abdel-Aziz El-Kak, Mohamed Lotfy, Israa Saghier
The effect of rate control and rhythm control on left ventricular (LV) function in patients (pts) with atrial fibrillation (AF) and ischemic (LV) failure need to be delineated.
Methods:
The study was conducted on 48 pts with persistent AF of more than one week and less than one year duration and ischemic LV failure (EF < 50%). They were randomized into two groups matched in age and gender. Group 1: 24 pts submitted to rate control treatment. Group 2: 24 pts submitted to rhythm control treatment. Exclusion criteria: previous thromboembolism, left atrial (LA) or LA appendage thrombi, LA > 60 mm, intractable heart failure. Myocardial performance index (Tei index) was determined. Rate control: was achieved using digoxin, carvedilol, bisoprolol. Precardioversion TEE was done within 24 h of cardioversion. All pts received warfarin.
Results: Heart rate on admission and after one month follow up (mean): G1: 96 then 78. G2: 95 then 74. All improvement of LV function was statistically insignificant. NIHA class II, III and IV: G1: 100% then 66%, G2: 91% then 58%. The EF increased from 41% to 46% and 42% to 47%. Fractional shortening: G1 20 to 23; G2 20 to 23. Tei index improved in both groups: 1.4 and 0.96 to 1.27 and 0.74. LA diameter G1 50 mm to 52; G2 48 to 46.
Conclusions: Both rate and rhythm control strategies are effective in controlling HR equally. There is no difference between both strategies in improvement in LV function after one month of therapy. 
